Thomas Clairmont, MD
Internal Medicine · Portsmouth, NHNPI 1053415794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boehringer Ingelheim at 30.3% of the total. Reporting peaked in 2021 at $276 and has fallen 58.4% since, to $115 in 2024. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $79.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$239
- AbbVie$175
- Amgen$122
- Pfizer$88
- Johnson & Johnson$86
- Bayer$70
- plus $12 from 1 others
What the payments were for
- Food & beverage$78099%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $239 |
| AbbVie(2 entities) | 3 | $175 |
| Amgen | 1 | $122 |
| Pfizer | 1 | $88 |
| Johnson & Johnson | 1 | $86 |
| Bayer | 1 | $70 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$791 in reported general payments places this provider in the 90th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 124 | $157,899 |
| JardianceEmpagliflozin | 103 | $95,956 |
| TrulicityDulaglutide | 80 | $93,861 |
| OzempicSemaglutide | 34 | $45,970 |
| MounjaroTirzepatide | 27 | $43,590 |
| RybelsusSemaglutide | 14 | $33,418 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $29,852 |
| XareltoRivaroxaban | 14 | $18,905 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $18,663 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $14,295 |
| Rosuvastatin Calcium | 598 | $10,271 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,532 |
| Metoprolol Succinate | 366 | $6,429 |
| Telmisartan | 175 | $5,627 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $5,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $157,899124 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $12 | $137,451107 claims |
| Boehringer IngelheimJardiance | $239 | $95,956103 claims |
| Johnson & JohnsonXarelto | $86 | $18,90514 claims |
| AbbVieSynthroid | $175 | $1,83146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Portsmouth
- Brian HyettPortsmouth$185K
- Magued Rizkalla HannaPortsmouth$26K
- Katelyn HansonPortsmouth$1K
- Myhanh NguyenPortsmouth$620
- Donald RainoneLondonderry$1.9M
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
- William MonacoLebanon$97K
- Kevin PhoNashua$40K
- Mary McGowanLebanon$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.